NewcelX Aktie
| 4,09USD | -0,06USD | -1,45% |
WKN DE: A41SEM / ISIN: CH1442297896
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 6 | 6 | 2 | 4 | 3 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 0 | 6 | 9 | 2 | 2 |
| Summe Anlagevermögen | 1 | 0 | 0 | 0 | 0 |
| Summe Aktiva | 1 | 6 | 9 | 2 | 2 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 10 | 5 | 6 | 11 | 1 |
| Summe Eigenkapital | -9 | 1 | 3 | -9 | 1 |
| Summe Passiva | 1 | 6 | 9 | 2 | 2 |
Adresse
| The Circle 6, 8058 Kloten | |
| Telefon | +41 (44) 512-21-50 |
| Internet | http://newcelx.net |
Management
|
Alexander C. Zwyer
Director |
|
Ariel Revel
Director-Medical Affairs |
|
Eran Israel Iohan
Independent Director |
|
Eric Konofal
Head-DOXA Program |
|
Kfir Molakandov
Vice President-Research & Development |
|
Liora Oren
Independent Director |
|
Michel Revel
Director & Chief Scientific Officer |
|
Olivier Samuel
Independent Director |
|
Ronen Twito
Executive Chairman & Chief Executive Officer |
|
Sarah Bazak
Investor Relation Contact |
|
Tamar Galili
Director |
|
Uri Ben-Or
Chief Financial Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.